Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

Tomas Kalincik, Dana Horakova, Tim Spelman, Vilija Jokubaitis, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Csilla Rozsa, Pierre Grammond, Raed Alroughani, Pierre Duquette, Marc Girard, Eugenio Pucci, Jeannette Lechner-Scott, Mark Slee, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Raymond Hupperts, Freek Verheul, Suzanne HodgkinsonCelia Oreja-Guevara, Daniele Spitaleri, Michael Barnett, Murat Terzi, Roberto Bergamaschi, Pamela McCombe, Jose Sanchez-Menoyo, Magdolna Simo, Tunde Csepany, Gabor Rum, Cavit Boz, Eva Havrdova, Helmut Butzkueven

Research output: Article

102 Citations (Scopus)

Abstract

Objective: In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly compared the outcomes of switching to either of these agents. Methods: Using MSBase, a large international, observational, prospectively acquired cohort study, we identified patients with relapsing-remitting multiple sclerosis experiencing relapses or disability progression within the 6 months immediately preceding switch to either natalizumab or fingolimod. Quasi-randomization with propensity score-based matching was used to select subpopulations with comparable baseline characteristics. Relapse and disability outcomes were compared in paired, pairwise-censored analyses. Results: Of the 792 included patients, 578 patients were matched (natalizumab, n = 407; fingolimod, n = 171). Mean on-study follow-up was 12 months. The annualized relapse rates decreased from 1.5 to 0.2 on natalizumab and from 1.3 to 0.4 on fingolimod, with 50% relative postswitch difference in relapse hazard (p = 0.002). A 2.8 times higher rate of sustained disability regression was observed after the switch to natalizumab in comparison to fingolimod (p<0.001). No difference in the rate of sustained disability progression events was observed between the groups. The change in overall disability burden (quantified as area under the disability-time curve) differed between natalizumab and fingolimod (20.12 vs 0.04 per year, respectively, p<0.001). Interpretation: This study suggests that in active multiple sclerosis during treatment with injectable disease-modifying therapies, switching to natalizumab is more effective than switching to fingolimod in reducing relapse rate and short-term disability burden.

Original languageEnglish
Pages (from-to)425-435
Number of pages11
JournalAnnals of Neurology
Volume77
Issue number3
DOIs
Publication statusPublished - márc. 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Kalincik, T., Horakova, D., Spelman, T., Jokubaitis, V., Trojano, M., Lugaresi, A., Izquierdo, G., Rozsa, C., Grammond, P., Alroughani, R., Duquette, P., Girard, M., Pucci, E., Lechner-Scott, J., Slee, M., Fernandez-Bolanos, R., Grand'Maison, F., Hupperts, R., Verheul, F., ... Butzkueven, H. (2015). Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Annals of Neurology, 77(3), 425-435. https://doi.org/10.1002/ana.24339